Benzinga
10 Feb 2026, 16:12 UTC · 35w ago
Verdict
Headline leans bullish. We score PHIO +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Phio Pharmaceuticals' Phase 1b trial of PH-762 showed an 85% pathological response rate at the highest dose, with complete tumor clearance in four of six responders.
So whatHigh efficacy and tumor clearance in a cancer trial are primary catalysts for biotech valuations, especially for micro-cap companies.
More positive than 99% of claims this week
The Safety Monitoring Committee reported no serious adverse events or dose-limiting toxicities across all five dose escalation cohorts for PH-762.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 94% of claims this week
The company targets an FDA submission for guidance on next-step clinical study design in the second quarter of 2026.
More positive than 81% of claims this week
Manufacturing of cGMP material is expected to commence in the second half of 2026, with non-human primate studies planned for March 2026.
More positive than 69% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company's stock surged following a Phase 1b trial showing significant tumor clearance and an 85% pathological response rate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
−3.3%
Price is moving against the score
$0.8700 vs $0.9000 close before publication (Feb 9) · not market-adjusted
PHIO chart →
